The selling price would be in the range of 560 rupees and 562.30 rupees per share, the report said
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Biocon Sells 9.96% Stake In Contract Research Firm Syngene Via Open Market
Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing
Topics
Biocon | biocon stock | Stake sale
BENGALURU (Reuters) - Indian biopharma company Biocon sold a 9.96% stake in its unit and contract research firm Syngene International through open market sale, it said in an exchange filing on Wednesday.
With the sale, the total promoter stake of Biocon in Syngene stands at 54.6%, the exchange filing showed.
Biocon did not reveal the price at which the stake was sold.
Officials at Syngene and Biocon did not immediately respond to a Reuters query seeking the reason for the stake sale and the price at which the sale was executed.
Biocon was selling the stake in Syngene to fund the acquisition of Viatris Inc's biosimilars business that it announced last year, CNBC TV-18 reported on Tuesday.
The selling price would be in the range of 560 rupees and 562.30 rupees per share, the report said.
Biocon Biologics had in February 2022 said it would buy the U.S. drug maker's biosimilars business in a deal valued at $3.34 billion.
Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing.
Biocon's shares closed up 2%, while those of Syngene added 0.74% on Wednesday.
(Reporting by Nallur Sethuraman in Bengaluru; Editing by Dhanya Ann Thoppil)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Wed, February 01 2023. 19:33 IST
RECENT NEWS
HSBC Swings The Axe At UK Wealth In An AI Push
HSBC is preparing deep job cuts across its UK wealth management arm. It plans to cut about half of its management and sp... Read more
Kraken's Owner Buys A Bank: The Lines Are Blurring
Payward, the parent company of the crypto exchange Kraken, has agreed to buy a European bank. It would be the first digi... Read more
Revoluts Australian Banking Licence Game Changer
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
The AI Bank Is Coming, But Who Controls The Risk?
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank UK Profit Leads To European Growth
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
Bank Of London Continues To Rebuild
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more